TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06632652

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: Provide 'Health Education' for acquisition of self-management skills, acquiring knowledge of both the disease and self-care. By making self-supported decisions, the patients are able to manage their diet, exercise and medication.~Patients will start implementing diabetes management right after the group education. Each patient will develop monthly goal settings (behavior change plan) related to their diabetes management, daily practice them, and record the results every day on the self-monitoring notebook. The nurses call each patient on the scheduled day, ask/evaluate his/her behavior changes and monitored data, then make step-up goals for the next month. In addition, based on his/her knowledge and practice level, the nurses provide education using the education booklet. Patients and the nurses repeat these activities during 6 months.
Study: NCT04805515

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nicotine Corrective Messages
Description: Messages communicating misperceptions of nicotine's role in health harms as well as misperceptions about reduced nicotine content cigarettes and e-cigarettes.
Study: NCT06294418

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Field Cycling Imaging (FCI)
Description: FCI scan
Study: NCT04731987

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Beverage consumption
Description: Volunteers will consume, in random order, daily 330 ml of 1 experimental beverage per period (Orange Juice, Control Beverage, Control Beverage supplemented with hesperidin) for 6 weeks in each period.~At the beginning and the end of each period, exploration will be conducted at fasted state and at post-prandial state after the administration of a high-fat high-sugar meal.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beverage consumption
Description: Volunteers will consume, in random order, daily 330 ml of 1 experimental beverage per period (Orange Juice, Control Beverage, Control Beverage supplemented with hesperidin) for 6 weeks in each period.~At the beginning and the end of each period, exploration will be conducted at fasted state and at post-prandial state after the administration of a high-fat high-sugar meal.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beverage consumption
Description: Volunteers will consume, in random order, daily 330 ml of 1 experimental beverage per period (Orange Juice, Control Beverage, Control Beverage supplemented with hesperidin) for 6 weeks in each period.~At the beginning and the end of each period, exploration will be conducted at fasted state and at post-prandial state after the administration of a high-fat high-sugar meal.
Study: NCT05307809

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample collection
Description: Blood sample collection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample collection
Description: Blood sample collection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample collection
Description: Blood sample collection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin sample collection
Description: Skin sample collection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin sample collection
Description: Skin sample collection
Study: NCT05226585

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-Person Cognitive Behavioral Therapy for Insomnia
Description: Cognitive behavioral therapy is recommended as a first-line treatment for insomnia (CBTi). CBTi contains the following well-validated components of cognitive behavioral treatment for insomnia: stimulus control, sleep compression, sleep hygiene, relaxation training, and cognitive restructuring.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telehealth Cognitive Behavioral Therapy for Insomnia
Description: Telehealth cognitive behavioral therapy is recommended as a first-line treatment for insomnia (CBTi) conducted via audio-video communication. tCBTi contains the following well-validated components of cognitive-behavioral treatment for insomnia: stimulus control, sleep compression, sleep hygiene, relaxation training, and cognitive restructuring.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet Cognitive Behavioral Therapy for Insomnia
Description: Sleep Healthy Using The Internet (SHUTi; aka iCBTi) is a self-guided, fully automated, online CBTi program that includes interactive features: personalized goal setting, graphical feedback based on inputted data, animations/illustrations to enhance comprehension, patient vignettes, and video-based expert explanations.
Study: NCT06386861

Intervention type: OTHER
Group type: OTHER
Intervention: Attitudes Toward Genomics and Precision Medicine (English)
Description: completing the English version of the AGPM and validated health literacy and numeracy instruments

Intervention type: OTHER
Group type: OTHER
Intervention: Attitudes Toward Genomics and Precision Medicine (Spanish)
Description: completing the Spanish version of the AGPM and validated health literacy and numeracy instruments
Study: NCT05980338

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: genicular nerve ablation by thermal radiofrequency
Description: radio-frequency will be done using the Neurotherm NT1100 re-generator. The 3 entry sites will be detected under fluoroscopy then local anesthesia will be performed using lidocaine 2% followed by the insertion of the 3 radiofrequency cannulas (STRYKER 20 G, 9 cm with 1 cm active tip) targeting the 3 main nerves ( superior medial genicular, superior lateral genicular and the inferior medial genicular nerves ) .~A confirmation of the targeted sites is done under fluoroscopy in both A-P and lateral views then a motor stimulation will be done to ensure no undesirable motor response followed by lidocaine 1 % injection and placing of the radiofrequency cables and ablation was done at 80 degrees for 90 seconds . The procedure will be repeated 3 times at different levels in the lateral view separated by 0,5 cm to ensure successful targeting. Then remove the needles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: genicular nerve ablation by thermal radiofrequency
Description: radio-frequency will be done using the Neurotherm NT1100 re-generator. The 3 entry sites will be detected under fluoroscopy then local anesthesia will be performed using lidocaine 2% followed by the insertion of the 3 radiofrequency cannulas (STRYKER 20 G, 9 cm with 1 cm active tip) targeting the 3 main nerves ( superior medial genicular, superior lateral genicular and the inferior medial genicular nerves ) .~A confirmation of the targeted sites is done under fluoroscopy in both A-P and lateral views then a motor stimulation will be done to ensure no undesirable motor response followed by lidocaine 1 % injection and placing of the radiofrequency cables and ablation was done at 80 degrees for 90 seconds . The procedure will be repeated 3 times at different levels in the lateral view separated by 0,5 cm to ensure successful targeting. Then remove the needles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: genicular nerve ablation by thermal radiofrequency plus alcohol neurolysis
Description: radio-frequency will be done using the Neurotherm NT1100 re-generator. The 3 entry sites will be detected under fluoroscopy then local anesthesia will be performed using lidocaine 2% followed by the insertion of the 3 radiofrequency cannulas (STRYKER 20 G, 9 cm with 1 cm active tip) targeting the 3 main nerves of the knee.~A confirmation of the targeted sites is done under fluoroscopy in both A-P and lateral views then a motor stimulation will be done to ensure no undesirable motor response followed by lidocaine 1 % injection and placing of the radio-frequency cables and ablation was done at 80 degrees for 90 seconds . The procedure will be repeated 3 times at different levels in the lateral view. After the radiofrequency is done at each level a 1 ml of 70% alcohol will be injected making a total of 3 ml injection to each nerve Then remove the needles.
Study: NCT05518708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3032950
Description: BI 3032950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3032950
Description: BI 3032950

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04816318

Intervention type: OTHER
Intervention: Social and public health measures against COVID-19
Description: 1. Viral spread (for both outcomes) 1.1. Total lockdown 1.2 Partial lockdown (geographical, step-wise/graduated response) 1.3 Curfew 1.4 School closure 1.5 Closure of shopping malls, gyms, churches, parks 1.6 Remote work 1.7 Restrictions to national/subnational mobility 1.8 Prohibition of mass gatherings~2. Health systems response (for COVID-19 deaths outcome) 2.1 Interventions to increase testing capacity 2.2 Interventions to increase the number of ICU/critical beds~3. Mitigation strategies (for both outcomes) 3.1 Direct social assistance (in-kind/cash) 3.2 Cash transfer 3.3 Withdrawal of pension funds

Intervention type: OTHER
Intervention: Control
Description: The comparator is a counterfactual outcome defined as the projection of the pre-intervention trend to simulate what would have happened if the policy had not occurred (see Statistical Analysis Plan for definitions)
Study: NCT06133296

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional fixed treatment
Description: Roth brackets (.018; Gemini Roth System, 3M Unitek, USA) were used for the fixed orthodontic attachment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clear aligner treatment
Description: After the clear aligners came from the manufacturer (Align Technology, Santa Clara, CA), the compatibility of the guide aligner with each patient's mouth was checked for attachments
Study: NCT03966131

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tongue pressure recordings with the PRESLA prothesis for the Arm1 (patients wearing the complete denture for the first time)
Description: Tongue pressure recordings during speech production, wet and dry swallowing tasks planned in 3 sessions, when the complete denture is worn for the first time, after 3 weeks, then after 3 months in order to characterise the adaptation to this new prosthesis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tongue pressure recordings with the PRESLA prothesis for the Arm2 (patients used to wear the complete denture)
Description: These measures provide to establish a spatial and temporal mapping of contacts applied by the tongue and lips to the prosthesis during speech production in patients used to their prosthesis. They also provide to establish a spatial and temporal mapping of contacts applied by the tongue and lips to the prosthesis during swallowing) in these patients. The measurement is made at once when the new denture which replaces the old one is placed in the mouth.
Study: NCT04830124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemvaleukin Alfa Subcutaneous
Description: Subcutaneous injection of nemvaleukin every 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemvaleukin Alfa Intravenous
Description: Intravenous (IV) infusion over 30 minutes given daily for 5 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemvaleukin Alfa Intravenous Less Frequent Dosing
Description: Intravenous (IV) infusion over 30 minutes twice every 21 days (Day 1 and Day 8 dosing of a 21 day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemvaleukin Alfa Intravenous Less Frequent Dosing
Description: Intravenous (IV) infusion over 30 minutes twice every 21 days (Day 1 and Day 8 dosing of a 21 day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Cohort 4 only: 200mg IV pembrolizumab on Day 1 of a 21-day cycle
Study: NCT05188703

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Participants will be assigned to a patient navigator and will have quarterly appointments. Patient navigators will assist with access and coordination of medical care.
Study: NCT06026501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PE0116,PE0105
Description: 1. PE0116: 4-1BB Agonist Antibody Drug~2. PE0105: PD-1 Monoclonal Antibody Drug
Study: NCT05097105

Intervention type: DEVICE
Intervention: MRI
Description: MRI sequences: TI. T2 and diffusion weighted
Study: NCT06402292

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OSTEOMYELITIS SURGICAL TREATMENT WITH LOCAL ANTIBIOTICS AND PEROSSAL
Description: 25 PATIENTS WITH FRI WILL BE SURGICALLY TREAT WITH DESBRIDMENT AND PEROSSAL WITH ANTIBIOTCS
Study: NCT06505993

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Communication
Description: Participants will experience a coordinated social marketing campaign including targeted messaging related to vaccine education, self-efficacy, and informative resources to receive the COVID-19 vaccine. The intervention messaging will be strategically layered and disseminated to this intervention arm predominately via Facebook by trusted and local communicators in the study counties.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Communication + Structural
Description: This multi-level intervention will include the defined health messaging intervention components, as well as a combination of structural-level intervention strategies targeted to better facilitate access to community-based vaccination delivery. Health organizations will receive a toolkit, which will include community-specific resources and training modules such as: up to date evidence-based vaccination guidance that can be delivered to patients; strategies for navigating conversations with patients about vaccination; any applicable reimbursement, insurance, or qualifying enrollment information specific to the healthcare organization; identifying locations that facilitate access for the community members; provided advertising to promote the locations and timing of the vaccinations; and generating community-based branding for all vaccination delivery based on the trusted information sources identified.
Study: NCT06199011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine hydrochloride
Description: A standardized non-opioid anesthesia will be achieved by using continuous intraoperative infusion of esketamine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid
Description: A standardized opioid anesthesia will be achieved by using continuous intraoperative infusion of opioids.
Study: NCT04281355

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Omission of axillary lymph node dissection
Description: Axillary lymph node dissection will be replaced by axillary radiotherapy in Randomisation B

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Omission of axillary lymph node dissection
Description: Axillary lymph node dissection will be replaced by axillary radiotherapy in Randomisation B

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Omission of regional irradiation
Description: Regional irradiation will be omitted in the interventional arm of Randomisation A.
Study: NCT05570071

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy
Description: medical treatment of pelvic floor

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: physical therapy
Description: medical treatment of pelvic floor
Study: NCT06547515

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Sleeve gastrectomy

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Sleeve gastrectomy

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Sleeve gastrectomy
Study: NCT04799691

Intervention type: PROCEDURE
Intervention: Invasive ventilation strategy
Description: Use of an invasive ventilatory support strategy

Intervention type: PROCEDURE
Intervention: Non-invasive ventilation strategies
Description: Use of non-invasive ventilatory support strategies
Study: NCT05314933

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2-Deoxyglucose
Description: Intranasal administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intranasal administration
Study: NCT04845139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab given intraventricularly
Study: NCT05837104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium vitamin B6
Description: Magnesium citrate (100mg) and Pyridoxine hydrochloride (10mg) in tablet form, taken three times daily for four weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet, three times daily for four weeks.
Study: NCT06194500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-LY3549492
Description: Administered as oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3549492
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-LY3549492
Description: Administered as IV infusion.
Study: NCT05323071

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose 24%
Description: According to the age of the newborn:~24-26 weeks : 0.1 mL, 27-31weeks : 0.25 mL, 32-36 weeks : 0.5 mL, \>37 weeks : 1 mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose 24%
Description: According to the age of the newborn:~24-26 weeks : 0.1 mL, 27-31weeks : 0.25 mL, 32-36 weeks : 0.5 mL, \>37 weeks : 1 mL
Study: NCT06269237

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: M22
Description: Participants in the group with 3 sessions of IPL, 2 weeks apart. Device: Intense pulsed light IPL treatment intensity was chosen based on the Fitzpatrick scale as follows: Fitzpatrick scale I, II, III, 10-15 J/cm2 with a 570-nm filter.~Other Names:~• IPL

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: M22
Description: Participants in the group with 3 sessions of IPL, 2 weeks apart. Device: Intense pulsed light IPL treatment intensity was chosen based on the Fitzpatrick scale as follows: Fitzpatrick scale I, II, III, 10-15 J/cm2 with a 570-nm filter.~Other Names:~• IPL

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham M22
Description: Participants in the group with 2 sessions of IPL, 1 session of sham IPL, 2 weeks apart. Device: Intense pulsed light IPL treatment intensity was chosen based on the Fitzpatrick scale as follows: Fitzpatrick scale I, II, III, 10-15 J/cm2 with a 570-nm filter.
Study: NCT05558462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC8
Description: A single dose of R or T drug in each of 2 periods of the study in fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC8
Description: A single dose of R or T drug in each of 2 periods of the study in fasted conditions
Study: NCT05962359

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-Implemented Communication Treatment
Description: The intervention will be taught by a qualified professional online and/or in-person for about 6 months. Parents will learn strategies to enhance their children's social communication and will receive coaching and feedback.
Study: NCT04779489

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: personalized ultrafractionated stereotactic ablative radiotherapy
Description: next-generation stereotactic ablative radiotherapy to bladder and enlarged lymph nodes
Study: NCT06373887

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: plant-based Low carbohydrate diet
Description: In the research, the high, medium, low carbohydrate degradation subjects were randomized to either plant-based Low carbohydrate diet or low fat diet to loss weight.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: plant-based Low low fat diet
Description: In the research, the high, medium, low carbohydrate degradation subjects were randomized to either plant-based Low carbohydrate diet or low fat diet to loss weight.
Study: NCT06428812

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: perineal package application group
Description: This group includes those in the 2nd stage of labor upright position spontaneous pushing Hot application will be made
Study: NCT04732949

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SNG001
Description: SNG001 nebuliser solution, 2 syringes each containing 0.65 mL once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nebuliser solution, 2 syringes each containing 0.65 mL solution containing excipients of the SNG001 solution
Study: NCT00771121

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: urea/lactic acid
Description: new emulsion type

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: only emulsion base
Study: NCT04861428

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IQOS
Description: IQOS is a heat-not-burn tobacco product (consisting of an electronic heating device and Heatstick tobacco rods).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IQOS
Description: IQOS is a heat-not-burn tobacco product (consisting of an electronic heating device and Heatstick tobacco rods).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smoking as Usual
Description: Cigarette smoking

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking as Usual
Description: Cigarette smoking
Study: NCT06047496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted eating
Description: Caloric intake restricted to a self-defined 8-10 hour window in each 24-hour period.
Study: NCT05191953

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral ultrasound-guided ESPB
Description: Bilateral ultrasound-guided ESPB (total of 40 ml, 0.25% bupivacaine) will be performed.~Intraoperative analgesia:~At the end of the surgery, all patients will be given 0.05 mg/kg morphine IV. Postoperative analgesia: Paracetamol 1 gr IV (every 6 hours) and IV PCA of 0.5 mg/ml morphine (demand dose 20μg/kg; lock out interval 6-10 min.; the 4-hour limit will be 80% of the total calculated dose). In cases where rescue analgesia is required (NRS score ≥4) tramadol 100 mg IV will be infused within 30 minutes (max. 300 mg / day). For postoperative nausea and vomiting prophylaxis, patients will be routinely administered ondansetron 4 mg IV 20 minutes before extubation, in the intensive care unit.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral ultrasound-guided ESPB and superficial PIPB
Description: Bilateral ultrasound-guided ESPB (total of 40 ml, %0.25 bupivacaine) and Superficial PIPB (total of 20 ml, %0.25 bupivacaine) will be performed.~Intraoperative analgesia:~At the end of the surgery, all patients will be given 0.05 mg/kg morphine IV. Postoperative analgesia: Paracetamol 1 gr IV (every 6 hours) and IV PCA of 0.5 mg/ml morphine (demand dose 20μg/kg; lock out interval 6-10 min.; the 4-hour limit will be 80% of the total calculated dose). In cases where rescue analgesia is required (NRS score ≥4) tramadol 100 mg IV will be infused within 30 minutes (max. 300 mg / day). For postoperative nausea and vomiting prophylaxis, patients will be routinely administered ondansetron 4 mg IV 20 minutes before extubation, in the intensive care unit.